Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics has reported Receivables for 8 years, with the latest figure at $44000.0 in Q2 2023.

• For the quarter ending Q2 2023, Receivables fell 97.62% year-over-year to $44000.0; the trailing twelve-month figure through Jun 2023 stood at $44000.0 (down 97.62% YoY), and the FY2022 full-year result was $1.9 million, down 6.84% from the prior year.
• Receivables for Q2 2023 stood at $44000.0, down from $1.9 million in the prior quarter.
• The five-year high for Receivables was $8.2 million in Q1 2019, with the low at $44000.0 in Q2 2023.
• Historically, Receivables has averaged $3.9 million across 5 years, with a median of $4.3 million in 2020.
• Annual changes were most pronounced in 2019 — Receivables soared 71.64% — and 2023, when it tumbled 97.62%.
• Avalo Therapeutics' Receivables stood at $5.2 million in 2019, then slipped by 16.35% to $4.4 million in 2020, then advanced by 9.44% to $4.8 million in 2021, then tumbled by 60.01% to $1.9 million in 2022, then tumbled by 97.71% to $44000.0 in 2023.
• The last three Receivables figures came in at $44000.0 (Q2 2023), $1.9 million (Q4 2022), and $1.3 million (Q3 2022), per Business Quant data.